Chris Moreau
Chief Executive Officer bei ALGERNON PHARMACEUTICALS INC.
Vermögen: 85 239 $ am 31.03.2024
Profil
Christopher Joseph Moreau is currently the Chief Executive Officer & Director at Algernon Pharmaceuticals, Inc. He previously held positions as the President, CEO, Director & Head-Investor Relations at Luminor Medical Technologies, Inc. from 2011 to 2015.
He also served as the Chief Executive Officer at Nash Pharmaceuticals, Inc. Additionally, he was a Director at First Responder Technologies, Inc. from 2019 to 2020.
He has also held the position of President at Advansis Capital Corp.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.04.2024 | 1 039 502 ( 5,19% ) | 85 239 $ | 31.03.2024 |
Aktive Positionen von Chris Moreau
| Unternehmen | Position | Beginn |
|---|---|---|
| ALGERNON PHARMACEUTICALS INC. | Chief Executive Officer | 01.03.2018 |
Ehemalige bekannte Positionen von Chris Moreau
| Unternehmen | Position | Ende |
|---|---|---|
| QUEBEC PEGMATITE HOLDINGS CORP. | President | 24.07.2019 |
Luminor Medical Technologies, Inc.
 Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Luminor Medical Technologies, Inc. engages in acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. It develops technology programs: Scout DS Diabetes Screen, PreVu Skin Cholesterol Test for fiabetes, and coronary artery disease. The company was founded on June 27, 1998 and is headquartered in Toronto, Canada. | Chief Executive Officer | 21.04.2016 |
Nash Pharmaceuticals, Inc.
 Nash Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nash Pharmaceuticals, Inc. engages in the research and development of repurposed therapeutic drugs and pharmaceutical products. Its focus areas include non-alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease. The company is headquartered in Vancouver, Canada. | Chief Executive Officer | - |
| Advansis Capital Corp. | President | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ALGERNON PHARMACEUTICALS INC. | Health Technology |
| Private Unternehmen | 4 |
|---|---|
Luminor Medical Technologies, Inc.
Luminor Medical Technologies, Inc. Miscellaneous Commercial ServicesCommercial Services Luminor Medical Technologies, Inc. engages in acquiring, developing and commercializing non-invasive technologies for unmet clinical needs. It develops technology programs: Scout DS Diabetes Screen, PreVu Skin Cholesterol Test for fiabetes, and coronary artery disease. The company was founded on June 27, 1998 and is headquartered in Toronto, Canada. | Commercial Services |
| Advansis Capital Corp. | |
First Responder Technologies, Inc.
 First Responder Technologies, Inc. Aerospace & DefenseElectronic Technology First Responder Technologies, Inc. is in the process of exploring business opportunities. The company was founded on January 27, 2017 and is headquartered in Vancouver, Canada. | Electronic Technology |
Nash Pharmaceuticals, Inc.
Nash Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Nash Pharmaceuticals, Inc. engages in the research and development of repurposed therapeutic drugs and pharmaceutical products. Its focus areas include non-alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease. The company is headquartered in Vancouver, Canada. | Health Technology |
